Drug Profile

Recombinant alpha-1 antitrypsin - Kamada

Alternative Names: Recombinant AAT - Kamada

Latest Information Update: 28 Feb 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Kamada
Class Acute-phase proteins; Alpha globulins; Anti-inflammatories; Antiallergics; Antihyperglycaemics; Blood proteins; Enzymes; Secretory proteinase inhibitory proteins; Serpins
Mechanism of Action Serine endopeptidase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

28 Feb 2025 No recent reports of development identified for preclinical development in Alpha-1-antitrypsin-deficiency in Israel
27 Jan 2021 Recombinant alpha-1 antitrypsin is available for licensing as of 27 Jan 2021. https://www.kamada.com/partnerships/
27 Jan 2021 Preclinical trials in Alpha 1-antitrypsin deficiency in Israel (unspecified route) before January 2021 (Kamada pipeline, January 2021)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com